Five Reasons Why GSK Spinning Off Consumer Health Wouldn't Be Easy
This article was originally published in The Rose Sheet
GSK once again provided grist to the stock market rumor mill recently with reports of its chairman talking to major shareholders about the possibility of splitting up the company. But there are reasons to doubt whether talks would lead to action any time soon.
You may also be interested in...
GSK removed some uncertainty about how much it could invest in pharma R&D and business development by purchasing Novartis' share of the firms' Consumer Healthcare Joint Venture. Now it can more accurately allocate capital as it prepares for battle in HIV and braces for Advair generics.
UK pharma giant GlaxoSmithKline has nabbed a high-profile figure from Google's Calico to head up its research efforts. Barron's oncology pedigree from his time at Roche suggests that cancer is again a core area for GSK.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the format of the content or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.